MedTrace Logo

A Clinical Feasibility Study of a Photoacoustic Finder

NCT06412211 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2024-05-14

No results posted yet for this study

Summary

Determining the prognosis of breast cancer relies significantly on axillary staging by sentinel lymph node biopsy (SLNb). The SLNb is generally performed using radioisotopes, blue dyes, or both to improve the false negative rate. However, a gamma probe with radioisotopes involves ionizing radiation, and blue dye detection relies on visual inspection by an operator. To overcome these limitations, the photoacoustic finder (PAF) was developed as a highly sensitive, non-radioactive detector that uses only blue dye and a photoacoustic signal to detect SLNs. To evaluate the PAF, its performance was compared with the standard SLN detection method for breast cancer patients.

Conditions

Interventions

DEVICE

Photoacoustic finder

Sentinel lymph node detector using photoacoustic signal

Sponsors & Collaborators

  • Pohang University of Science and Technology

    collaborator OTHER

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Dooreh Kim, MD · Seoul St. Mary's Hospital

Eligibility

Min Age
19 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-07
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412211 on ClinicalTrials.gov